22.728 articles found

USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE.

POUPARDIN-OLIVIER OLIVIA, DONGEN MARIA JOHANNA PETRONELLA VAN, AMAUDRUT JEROME, BOUBIA BENAISSA, GUILLIER FABRICE.

· 2012-03-12

Inertial sensing to determine movement disorder motion present before and after treatment.

Teskey WJ, Elhabiby M, El-Sheimy N.

Sensors (Basel) · 2012-03-12

DOI: 10.3390/s120303512PMID: 22737022

Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease.

Dobkin RD, Rubino JT, Allen LA, Friedman J, Gara MA, Mark MH, Menza M.

J Consult Clin Psychol · 2012-03-12

DOI: 10.1037/a0027695PMID: 22409644

Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues.

Manfredsson FP, Bloom DC, Mandel RJ.

Neurobiol Dis · 2012-03-09

DOI: 10.1016/j.nbd.2012.03.001PMID: 22426391

Directed evolution of novel adeno-associated viruses for therapeutic gene delivery.

Bartel MA, Weinstein JR, Schaffer DV.

Gene Ther · 2012-03-08

DOI: 10.1038/gt.2012.20PMID: 22402323

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Martinez-Fong D, Bannon MJ, Trudeau LE, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, Reyes-Corona D, Armendáriz-Borunda J, Navarro-Quiroga I.

Nanomedicine · 2012-03-07

DOI: 10.1016/j.nano.2012.02.009PMID: 22406187

The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.

Managò F, Espinoza S, Salahpour A, Sotnikova TD, Caron MG, Premont RT, Gainetdinov RR.

Sci Rep · 2012-03-05

DOI: 10.1038/srep00301PMID: 22393477

Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.

Maranis S, Stamatis D, Tsironis C, Konitsiotis S.

Eur J Pharmacol · 2012-03-04

DOI: 10.1016/j.ejphar.2012.02.036PMID: 22410193

Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA.

Neuroimage · 2012-03-03

DOI: 10.1016/j.neuroimage.2012.02.066PMID: 22406356

Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson's disease: a case-series study.

Donoyama N, Ohkoshi N.

J Altern Complement Med · 2012-03-02

DOI: 10.1089/acm.2011.0148PMID: 22385078

Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease.

Cova L, Bossolasco P, Armentero MT, Diana V, Zennaro E, Mellone M, Calzarossa C, Cerri S, Deliliers GL, Polli E, Blandini F, Silani V.

Apoptosis · 2012-03-01

DOI: 10.1007/s10495-011-0679-9PMID: 22160861

Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

Clin Neuropharmacol · 2012-03-01

DOI: 10.1097/wnf.0b013e31824523dePMID: 22377973